Study designed to assess side effects of immunotherapy for non-small cell lung cancer

April 17, 2018
The Lung Cancer Registry has launched a study designed to assess the side effects associated with use of immune checkpoint inhibitors for the…

Liquid biopsy platforms yield substantially different results

April 13, 2018
Two commercial liquid biopsy platforms that evaluated tumor samples from the same patient population yielded significantly different results…

‘Exaggerated’ early clinical trial results may create false hope

April 11, 2018
Researchers at Mayo Clinic identified an “exaggerated treatment effect” in more than one-third of early-phase clinical trials designed to…

Changing the paradigm of cytomegalovirus management among HSCT patients

HemOnc Today, April 10, 2018
Roy F. Chemaly, MD, MPH, FACP, FIDSA
Cytomegalovirus infection occurs among approximately 40% of cytomegalovirus-seropositive patients within the first 100 days following hematopoietic…

Tumor-treating fields extend survival in glioblastoma

April 4, 2018
The addition of tumor-treating fields to maintenance temozolomide therapy extended survival among a cohort of patients with glioblastoma, according…

Anti-PD-1 therapies show significant benefit in desmoplastic melanoma

March 29, 2018
Single-agent therapy with anti-PD-1 inhibitors induced response rates of 70% within a cohort of patients with metastatic desmoplastic melanoma. …

Report: Cost of CAR T-cell therapies aligns with clinical benefit

March 23, 2018
Chimeric antigen receptor T-cell therapy improved response rates and survival for patients with cancer who have exhausted most other options, and the…

Statins may reduce pediatric medulloblastoma tumor growth

March 23, 2018
Cholesterol may be required for medulloblastoma tumors to grow, study results showed. This finding suggests statins may be an effective therapy…

Novel nanomedicine agent may penetrate blood-brain barrier

March 21, 2018
A novel nanomedicine agent known as BXQ-350 has demonstrated the ability to cross the blood-brain barrier in patients with solid tumors, according to…

‘Window of opportunity’ exists for durvalumab as pancreatic cancer maintenance therapy

March 19, 2018
A randomized clinical trial is underway to assess the efficacy of the novel immunotherapy durvalumab as maintenance therapy for patients with…